Regional variations in US cancer imaging data: a warning for imaging overuse

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...
- Advertisement -

Danil V Makarov speaks to Gemma Westcott, Commissioning Editor: Danil V Makarov is an Assistant Professor and Director of Surgical Research in the Department of Urology at NYU Langone Medical Center.

 

In addition, he is an Assistant Professor in the Department of Population Health. His clinical areas of expertise include prostate cancer, benign prostatic hyperplasia, erectile dysfunction, kidney cancer, urinary tract infections, genitourinary neoplasm, elevated prostate-specific antigen and testicular cancer. In addition, his research interests are in the areas of prostate cancer, health policy and quality of care. An alumnus of the Johns Hopkins University School of Medicine (MD, USA), he completed his residency in urology at Johns Hopkins Hospital and a research fellowship at Yale University School of Medicine (CT, USA).

Q Can you tell our readers about your career to date?

I am a urologist and a health services researcher, and I take care of patients with prostate cancer and other urological malignancies clinically. I spend half of my time doing that and I spend the other half of my time doing health services research, which is the intersection between health policy, epidemiology and healthcare economics. I am particularly interested in the cost and quality of care for men with prostate cancer and how those are affected by changes in healthcare policy and the diffusion of new practices and innovations.

Latest stories

Related stories

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »